<DOC>
	<DOCNO>NCT01420341</DOCNO>
	<brief_summary>This randomise , open-labelled , controlled trial compare efficacy effectiveness relapse-free rate 12-week versus 20-week oral eradication treatment melioidosis . The study population include 800 patient culture-confirmed melioidosis 12 week oral eradication therapy complete without intravenous intensive antibiotic . Patients randomise either stop eradication treatment continue current oral treatment 8 week . The study aim optimise regimen use treat melioidosis well compliance reduce unnecessary use antibiotic .</brief_summary>
	<brief_title>Co-trimoxazole Maintenance Therapy Meliodosis</brief_title>
	<detailed_description>Planed interim analysis conduct patient enrollment reach 600 case evaluate safety futility study .</detailed_description>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>1 . Age &gt; 15 year 2 . Cultureconfirmed melioidosis 3 . Currently oral cotrimoxazole 12 ( +2 ) week without clinical evidence active melioidosis 4 . High likelihood complete least 6 month follow 5 . Willingness participate study write , informed consent obtain patient 1 . Pregnancy breast feed 2 . Contraindications TMPSMX : G6PD , severe adverse reaction grade 34 occur first 12 week treatment 3 . Relapse melioidosis least 2 year symptom free period last episode</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Meliodosis</keyword>
	<keyword>Co-trimoxazole</keyword>
	<keyword>Relapse</keyword>
</DOC>